SCHEMBL24635178

SCHEMBL24635178

CCc1nc2ccccc2c2c1ncn2CC(C)C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 7/20 0.70
PDE4D Q08499 2/20 0.70
POLB P06746 2/20 0.70
LMNA P02545 2/20 0.70
HRH2 P25021 1/20 0.70
ADRA1D P25100 1/20 0.70
HTR2A P28223 1/20 0.70
ADORA2A P29274 1/20 0.70
ADRA1A P35348 1/20 0.70
NUDT1 P36639 1/20 0.70
HTR2B P41595 1/20 0.70
KCNH2 Q12809 1/20 0.70
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TLR8 Q9NR97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13435161 0.84 TLR7 (0.74) TLR7PDE4DPOLBLMNAHRH2
Propionic Acid SCHEMBL6726615 0.84 TLR7 (0.63) TLR7PDE4DPOLBLMNAHRH2
Imiquimod SCHEMBL570774 0.83 TLR7 (1.00) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL1774913 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL30601166 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL4830500 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL1774937 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL4562038 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL14667666 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2
SCHEMBL29376434 0.83 TLR7 (0.72) TLR7PDE4DPOLBLMNAHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259254-A1 TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY TAMBO, INC. 2022-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259254-A1 TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY TIE1, CD74, MERTK TLR7 1267/4885PDE4D 3489/4885POLB 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.